- $7.35bn
- $6.72bn
- $36.13m
Merus NV expected to post a loss of 83 cents a share - Earnings Preview
Merus slumps on potential delay in cancer therapy filing, bigger Q3 loss
Merus NV reports results for the quarter ended in September - Earnings Summary
Brief: Merus NV Reports Quarterly Loss Per Share Of $0.53
Merus NV expected to post a loss of 63 cents a share - Earnings Preview
Brief: Merus NV says MCLA-129 Observed To Be Well Tolerated With A Favorable Safety Profile
Brief: Merus Announces Financial Results For The Second Quarter And Provides Business Update
Merus NV reports results for the quarter ended in June - Earnings Summary
Brief: Merus Presents Clinical Data On Zenocutuzumab (Zeno) In Nrg1-Fusion (Nrg1+) Cancer At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting (Oral Abstract)
U.S. STOCKS ON THE MOVE-Baidu Inc, Microsoft Corp, Meta Platforms
Pains and gains for cancer drugmakers ahead of industry meet
Merus on track for best day on promising cancer drug trial data
Pains and gains for cancer drugmakers ahead of industry meet
Elevation Oncology rises on promising data on cancer drug
Merus NV reports results for the quarter ended in March - Earnings Summary
Brief: Merus Announces Financial Results For The First Quarter 2022 And Provides Business Update
Merus NV expected to post a loss of 62 cents a share - Earnings Preview
Brief: Merus Reports Publication In Nature Cancer On Petosemtamab's Unique Mechanism Of Action
Brief: Merus Announces Financial Results For The Fourth Quarter And Full Year 2021 And Provides Business Update